Recurrent Glioblastoma Multiforme
20
1
2
12
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
10.0%
2 terminated out of 20 trials
85.7%
-0.8% vs benchmark
10%
2 trials in Phase 3/4
25%
3 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (20)
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma
Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme
Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV)
The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma
Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors
A Prospective, Open-label, Single-arm Clinical Study
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme
Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients
Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM
Procarbazine and Lomustine in Recurrent Glioblastoma
Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)
Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors
Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme
CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan
Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma
Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)